BridgeBio Pharma has presented late-stage data suggesting its transthyretin amyloidosis drug Attruby could gain an edge over Pfizer's tafamidis franchise in ATTR-CM, a closely watched rare heart-disease market.

Mankind Pharma (MNKI.NS) reported a sharp rise in quarterly profit on Tuesday, buoyed by robust demand for chronic therapies and consumer healthcare products, as the Indian drugmaker outpaced broader market growth at home even as rivals struggled with deteriorating conditions in the United States.

Sanofi [SNY] is stepping up its commitment to rare disease through two distinct partnerships, as the French pharmaceutical group seeks to strengthen its specialty care franchise and improve outcomes for patients with underdiagnosed conditions.

Novo Nordisk [NVO] suffered a setback to its drug pipeline on Tuesday after a treatment at the centre of a major acquisition produced disappointing results in a clinical trial for heart failure patients.

Jazz Pharmaceuticals, the Dublin-headquartered drugmaker, has delivered a markedly stronger first-quarter performance than analysts had anticipated, capping a twelve-month period in which the stock has more than doubled — and prompting a fresh debate over whether the equity now offers meaningful upside or has caught up with the underlying fundamentals.

Algeria has opened talks with Hungary on expanding bilateral cooperation in pharmaceutical manufacturing and clinical research, in the latest sign of the North African country's continuing push to attract foreign technical expertise into one of its more strategically prioritised industrial sectors.

Rocket Pharmaceuticals, the US gene therapy specialist, has bought itself an additional two years of operational runway through the $180mn sale of a regulatory voucher, easing pressure on a balance sheet that had been narrowing as the New Jersey-based group navigated a difficult phase of pipeline development and corporate restructuring.

aTyr Pharma shares declined sharply after the company announced plans for a new Phase 3 study of efzofitimod in pulmonary sarcoidosis following discussions with the U.S. Food and Drug Administration.

Brano Therapeutics raised $6.8 million in seed financing to support the development of new therapies targeting heart failure, including Heart Failure with preserved Ejection Fraction (HFpEF), an area where treatment options remain limited.

Zealand Pharma shares climbed after the company reported positive clinical progress across its obesity pipeline and strengthened its financial outlook with expected milestone payments from partner Roche.